- 1 - Title and Abstract
- 2 - Introduction
- 3-12 - Methods
- 3a - Trial design
- 3b - Changes to trial design
- 4a - Participants
- 4b - Study settings
- 5 - Interventions
- 6a - Outcomes
- 6b - Changes to outcomes
- 7a - Sample size
- 7b - Interim analyses and stopping guidelines
- 8a - Randomisation: sequence generation
- 8b - Randomisation type
- 9 - Randomisation: allocation concealment mechanism
- 10 - Randomisation: implementation
- 11a - Blinding
- 11b - Similarity of interventions
- 12a - Statistical methods
- 12b - Additional analyses
- 13-19 - Results
- 20-22 - Discussion
- 23-25 - Other information
Examples of Outcomes
This page contains examples of CONSORT Item 6a - Outcomes.
You can submit your own Examples here.
| The primary endpoint with respect to efficacy in psoriasis was the proportion of patients achieving a 75% improvement in psoriasis activity from baseline to 12 weeks as measured by the PASI [psoriasis area and severity index] Additional analyses were done on the percentage change in PASI scores and improvement in target psoriasis lesions. | ||
| Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. | Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. | Lancet. 2000;356:385-90. |
Help us to expand the Library of Examples by submitting your own.
Page last edited: 18 March 2011
